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Abstract
Background:  The AGREE instrument has been validated for evaluating Clinical Practice
Guidelines (CPG) pertaining to medical care. This study evaluated the reliability and validity of
physical therapists using the AGREE to assess quality of CPGs relevant to physical therapy practice.
Methods: A total of 69 physical therapists participated and were classified as generalists, specialist
or researchers. Pairs of appraisers within each category evaluated independently, a set of 6 CPG
selected at random from a pool of 55 CPGs.
Results: Reliability between pairs of appraisers indicated low to high reliability depending on the
domain and number of appraisers (0.17–0.81 for single appraiser; 0.30–0.96 when score averaged
across a pair of appraisers). The highest reliability was achieved for Rigour of Development, which
exceeded ICC> 0.79, if scores from pairs of appraisers were pooled. Adding more than 3
appraisers did not consistently improve reliability. Appraiser type did not determine reliability
scores. End-users, including study participants and a separate sample of 102 physical therapy
students, found the AGREE useful to guide critical appraisal. The construct validity of the AGREE
was supported in that expected differences on Rigour of Development domains were observed
between expert panels versus those with no/uncertain expertise (differences of 10–21% p = 0.09–
0.001). Factor analysis with varimax rotation, produced a 4-factor solution that was similar,
although not in exact agreement with the AGREE Domains. Validity was also supported by the
correlation observed (Kendall-tao = 0.69) between Overall Assessment and the Rigour of
Development domain.
Conclusion: These findings suggest that the AGREE instrument is reliable and valid when used by
physiotherapists to assess the quality of CPG pertaining to physical therapy health services.
Published: 02 March 2005
BMC Health Services Research 2005, 5:18 doi:10.1186/1472-6963-5-18
Received: 27 September 2004
Accepted: 02 March 2005
This article is available from: http://www.biomedcentral.com/1472-6963/5/18
© 2005 MacDermid et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
Page 2 of 12
(page number not for citation purposes)
Background
Clinical practice guidelines (CPGs) are one option for
promotion of quality in health services [1-6] Many coun-
tries are faced with common challenges in delivering
high-quality health care with available resources and have
pursued the development of CPGs as a means to optimize
effective and efficient care. As a result there is a need to
evaluate CPGs guidelines to assess their quality and their
impact on practice. The Appraisal of Guidelines for
Research and Evaluation (AGREE) instrument was devel-
oped by a group of researchers from 13 countries to pro-
vide a systematic framework for assessing guideline
quality[7,8] This instrument was thoroughly evaluated
and refined and is now a commonly used assessment
instrument for CPGs[2,3,9-13] A large-scale validation
study focussing primarily on medical (i.e. physician)
guidelines, was conducted supporting the reliability and
validity of this instrument[14].
The AGREE Collaboration published the development
process and associated reliability and validity data in
2003[14] This report outlined the rigorous process under-
taken to develop the AGREE instrument which included
item generation, selection and scaling followed by field-
testing and refinement. This process resulted in the final
instrument with 23 items distributed across six subscales
termed "domains", for which reliability and validity data
were presented. Reliability was determined by calculating
the internal consistency of each domain within the final
instrument and assessing the agreement between different
appraisers. A total of 33 guidelines were evaluated by the
four appraisers. Internal consistency ranged from 0.64–
0.88. 'Scope of Purpose' and 'Rigour of Development'
were the most homogeneous domains. The inter-rater
reliability exhibited a wide range from 0.25–0.91. Relia-
bility was higher with four appraisers and the most relia-
ble domain was 'Rigor of Development'. Higher reliability
within the domain of 'Rigor of Development' is a positive
finding, as this domain should contain items that are
more objective than items contained on other subscales of
the AGREE instrument. That is, because the 'Rigor of
Development' questions relate to the methodology of
developing a CPG and thus there are optimal criteria that
would be expected regardless of the content of the CPG. In
measurement terms, it is more likely that a "true" score
exists for elements within this domain. Therefore, varia-
bility observed on repeated assessments of the same CPG
should reflect measurement error between appraisers.
Other scales such as stakeholder involvement and applica-
bility might reasonably have different criteria depending
on clinical expertise or application. In measurement
terms, no single true score may exist for these items.
Therefore, variability observed between appraisers on
these domains might reflect a combination of measure-
ment error, as well as true variations in perspective. This
concept is important when assessing and interpreting the
reliability of evaluation instruments like the AGREE.
The AGREE Collaboration also assessed face, construct
and criterion validity of the AGREE Instrument. Face
validity was determined by surveying appraisers attitudes
and opinions about the instrument and its associated user
guide. Construct validity was determined by comparing
scores of guidelines in different subgroups to determine
whether they fit three specific constructs. The constructs
tested included whether established quality guideline pro-
grams produced guidelines with higher domain scores
than those developed outside of established systems;
whether guidelines supported by well-documented tech-
nical information had higher domain scores than those
without such documentation; and finally whether guide-
lines developed as national policies were higher quality
than regional or local CPGs. The first hypothesis was sup-
ported with respect to editorial independence, but not
other domains. The second and third hypotheses were
supported with respect to the domain Rigor of Develop-
ment, but not other domains. Finally, criterion validity
was determined by assessing the rank correlation between
appraisers domain scores and their overall assessment
scores (final item on the AGREE instrument). These corre-
lations were all highly significant (range Kendall's Tau-b =
0.67 – 0.88).
Physical therapy and other health care disciplines shares
common challenges in providing effective care within
limited resources. While many disciplines currently use
the AGREE the validation paper emphasized medical
practice and practitioners. The nature of physical therapy
practice differs substantively from medical practice in a
number of ways including access, funding, the nature of
interventions, research systems and professional associa-
tions; all of these might affect the type of CPGs, devel-
oped. Differences in training between disciplines might
also cause variations in how the AGREE was interpreted.
Additional validation with other settings or users would
strengthen the validation of the AGREE across a variety of
applications.
CPGs have arisen within the field of physical therapy from
a variety of sources[15,16] Professional associations have
assisted physical therapy practitioners in becoming aware
of the existence of such guidelines through websites and
newsletters. Ideally, information on the quality of such
guidelines should also be available to assist practitioners
in selecting between available guidelines. Currently, this
is not the case in physical therapy. While professional
associations may help co-ordinate the evaluation of
CPGs, they must inevitably must make decisions about
this process including which members of the profession
are able to evaluate CPGs, how many appraisers should beBMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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selected and which instrument should be used. For this
reason, our purpose was to determine whether the AGREE
instrument is a reliable and valid tool when used by phys-
ical therapists to assess CPGs that pertain to physical ther-
apy practice. Our hypothesis was that the AGREE
instrument would be a valid tool when used by physical
therapists to evaluate CPGs. Our secondary question was
whether an ideal number or type of physical therapist
appraiser would be evident from reliability data. We
hypothesized that 4 appraisers might be best, as the
AGREE Collaboration recommends " al least two apprais-
ers and preferably four as this will increase the reliability
of the assessment". [7]
Methods
This study was a cross-sectional study conducted to evalu-
ate inter-appraiser reliability and validity of quality
appraisal of CPGs performed by physical therapists using
the AGREE instrument Permission to use the AGREE
instrument was obtained from the AGREE Collaboration.
Ethics approval for this study was received from the Uni-
versity of Toronto, Office of Research Services.
Clinical practice guidelines
Clinical practice guidelines (CPGs) are "systematically
developed statements to assist practitioner and patient
decisions about appropriate healthcare for specific clinical
circumstances"[17]. The CPGs evaluated during this study
were identified through an inventory that was created by
the study authors from a series of systematic searches that
included electronic databases, websites, contact of profes-
sional associations and guideline developers. The inven-
tory included all located documents that were identified
by authors as Clinical Practice Guidelines. This inventory
was completed in 2002 and updated yearly and subse-
quently posted on the website for the Canadian and
Ontario Physiotherapy Associations (members only
access). Within this database, guidelines were categorized
according to the area of physical therapy practice (e.g.,
musculoskeletal, neurological, cardiorespiratory). Sixty
guidelines published in the last five years were selected
from this database for inclusion in the present study. Four
of these CPGs were excluded because they were not actu-
ally CPGs (e.g. systematic reviews included in error) and
one CPG was excluded because it was not relevant to
physical therapy. Thus in total, a sample of fifty-five
guidelines were evaluated in the present study.
Participants/training
All participants were physical therapists who were
recruited through advertisements in professional newslet-
ters. A total of 72 therapists responded to advertisements
and agreed to participate, 69 actually participated in train-
ing and study evaluations – two others had personal cir-
cumstances that prevented them from attending training
and one failed to respond further. The participants were
classified according to the following criteria: 1. Clinical
Specialists were Physical Therapists who were currently
practicing in a specific area, had a minimum of three years
experience and had participated in at least one post-grad-
uate course per year in their area of clinical expertise. 2.
Generalists were Physical Therapists practicing in a variety
of areas of physical therapy or an ongoing general prac-
tice, which covered a broad-spectrum of neurological,
orthopaedic and cardiorespiratory health problems. 3.
Researchers were Physical Therapists with or approaching
completion of a graduate research degree (M.Sc. and/or
PhD) with experience in conducting clinical trials or out-
comes research and experience in formal critical appraisal
of clinical research.
Demographic data was collected on all participants. Eligi-
ble participants were provided with training materials
which included the AGREE instrument (form and associ-
ated interpretation guidelines)[7,18] as well as a multiple-
choice test that required participants to answer questions
on the content and structure of the AGREE (see Additional
file 1). In addition, a sample guideline was provided to
participants with instructions to read the guideline (on
management of lymphedema following treatment for
breast cancer[19]) and appraise it using the AGREE instru-
ment and associated documentation.
Subsequently, all participants met by teleconference for
one hour with a subgroup (4–8) of study participants. The
sessions (a total of 6 teleconferences conducted) were led
by a single facilitator (first author). During this session
participants reviewed their responses to each question
and discussed their rationale or concerns regarding scor-
ing. The facilitator did not indicate a correct score for any
individual item. Participants were instructed that the
group facilitator would not indicate whether a given score
was correct, as this was not possible for many of the items.
Participants were directed to appreciate the difference
between items that had clear answers because they
inquired about specific factual information versus those
that had a subjective element where responses might vary
according to context. Participants were corrected if they
incorrectly interpreted the meaning of a given item on the
AGREE instrument. Although consensus was not the
objective of the training sessions, participants tended to
come to consensus after discussing items with colleagues
and a facilitator. In total, 69 appraisers attended the train-
ing sessions.
Appraisal instrument
The appraisal instrument used to evaluate the CPGs was
the AGREE [18]. This instrument consists of 23 items
organized in six domains ; each domain is intended toBMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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capture a separate dimension of guideline quality. The fol-
lowing domains are included:
1. Scope And Purpose: 3 items that address the overall aim
of the guideline, the clinical question and the target
population
2. Stakeholder Involvement: 4 items that address the compo-
sition, expertise and representation of the development
group
3. Rigor Of Development: 7 items that evaluate the process
used to locate and synthesize the evidence and to formu-
late and update the recommendations,
4. Clarity And Presentation: 4 items that address language
and format
5. Applicability: 3 items that address the potential organi-
zational, behavioural and cost implications of implemen-
tation and
6. Editorial Independence: 2 items that address potential
conflicts of interest.
Items are rated on a 4-point scale with endpoints of 4
'strongly agree' and 1 'strongly disagree'; the two mid-
points are 3 'agree' and 2 'disagree'. A section for overall
assessment is included at the end of the instrument that
requires the appraiser to make a judgment about the over-
all quality of the CPG. Appraisers are asked whether they
would 'strongly recommend', 'recommend (with provisos
or alterations)', 'would not recommend' or are 'unsure' if
they would recommend the CPG for practice.
Evaluation process
All participants completed the training program and pro-
ceeded to evaluate a set of 6 CPGs. These CPGs, six copies
of the AGREE instrument, and a pre-paid return were pro-
vided by mail. Each guideline was evaluated independ-
ently by three pairs of appraisers who were randomly
picked from the three pools of Physical Therapists (i.e.
two clinical specialists in the area of the CPG, two gener-
alists and two researchers). All appraisers returned their
packages, although up to 3 reminders calls were required
for late returns. Participants who completed the study
were provided with an honorarium ($100).
Data analysis
Data analysis was conducted to verify the quality of data,
assess instrument reliability and determine the validity of
the AGREE instrument for physical therapy practice. SPSS
statistical software for Windows (Version 11.0; SPSS Inc,
Chicago, Illinois) was used for all statistical analyses. P-
values of 0.05 or less were considered significant.
Data Entry/Quality
Data entry was completed by a single research assistant
who inspected data for errors once the data file was com-
plete. The first author conducted random checks of data
entry against original data sheets. Descriptive statistics
were conducted to identify outliers or unusual values.
Domain scores of each CPG were calculated as recom-
mended by the AGREE Collaboration. The scores of the
individual items in the domain were summed and stand-
ardized as a percentage of the maximum possible score for
that domain (AGREE Collaboration, 2001).
Reliability analyses
The internal consistency of each domain was evaluated
using Cronbach's Alpha. The reliability between apprais-
ers was determined for each question and each domain of
the AGREE. Intraclass correlation coefficients (ICC 1,1)
were calculated within each pair of appraisers and across
the pool of appraisers. A one-way random effects model
was used as pairs of appraisers were randomly selected
from our pool of physical therapist appraisers. An
unweighted and quadratic weighted kappa were calcu-
lated to indicate the agreement within pairs of appraisers
on whether a CPG was appropriate for clinical utilization.
ICCs or kappa values above 0.75 were considered to rep-
resent good, 0.40–0.75 moderate and <0.40 poor
reliability[20]
Validity analyses
Face validity
The face validity of the instrument for physical therapy
practice was determined from feedback provided on the
instrument from two sources. Participants (experienced
physical therapists) in the study were invited to provide
feedback at the training sessions (open-ended questions
regarding the training session and the AGREE itself -verbal
response). They were also asked to add comments about
any items, any issues with clarity or concerns directly on
their AGREE form when they were using the AGREE on
their assigned CPGs. These were returned, by mail, with
their ratings. In addition, over the course of two years, a
sample of 102 entry-level-masters trainees at McMaster
University were provided the training materials (except
for multiple-choice questionnaire) and were required to
complete an assignment where they evaluated the same
CPG[19] used during the study training session. This
assignment consisted of a facilitated group component
where students worked in groups of 4–6 to complete the
AGREE evaluation for the assigned CPG. The individual
component of this assignment required each student to
write a 1–2 page essay evaluating the instrument itself in
standardized domain score
obtained score minimum possible 
=
− s score
maximum possible score  minimum possible score
x100
−BMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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terms of its relevance to clinical practice, validity and their
personal preference about whether they would use it
again. This information was summarized by the course
instructor (first author) and the percentage of students
who responded that they would use the instrument again
was tabulated.
Factor (domain) validity
The validity of the domain structure was evaluated using
a principal components, varimax rotated factor analysis.
Item means across all 6 appraisers were entered into the
analysis. Coefficients were evaluated to determine
whether they supported the domain structure and fol-
lowed a similar pattern as to that reported for a previous
factor analysis published by the AGREE Collaboration.
Construct Validity
Construct validity was assessed by evaluating 2 hypothe-
ses. The first hypothesis was selected to match the hypoth-
esis tested by the AGREE Collaboration guidelines[14]
and supported by others[21,22], that CPGs developed by
established guideline developers should have higher qual-
ity scores than those created outside of established system.
All guidelines in the database were classified as having
been developed by established guideline developers if it
could be identified that an experienced guideline devel-
oper or development group was responsible for a specific
guideline. A CPG was classified as having "Experienced
Guideline Developers" if it 1) had more than 3 authors
(also fulfilled by an agency) and 2) at least one team
member could be identified an a methodologist experi-
enced in CPG development – either by descriptions con-
tained within the body or the CPG or after a review of
listed authors (conducted by JM and DB). If this could not
be verified the CPG was classified as " No or Uncertain
Methodology Expertise". Our second hypothesis was that
physical therapists would be more likely to recommend a
guideline that was rated as having higher Rigor of Devel-
opment scores. An independent t-test was used to evaluate
the scores obtained for Rigor of Development for guide-
lines judged as acceptable versus those that were not. This
hypothesis test is not ideal, as we are testing whether this
subscale contributes to the overall rating within the same
instrument. Nevertheless, in the absence of an external cri-
terion, we choose to use this analysis given that it was also
conducted in the original validation paper and there was
an advantage to having a comparable analysis.
Criterion validity
Finally, criterion validity was assessed in the same manner
as reported by the AGREE Collaboration in their valida-
tion study. Again we recognize we did not have an exter-
nal criterion. Kendall Tau B Rank correlation coefficients
were calculated between the appraisers domain scores and
the overall assessment score.
Results
Participants
Sixty-nine physical therapists were recruited and were cat-
egorized as clinical specialists (n = 29), generalists (n =
21) or researchers (n = 19) (Table 1). Generalists and spe-
cialists reported similar years of clinical experience with
generalists ranging from 3–33 (mean ± SD,16 ± 11) years
and specialists 3–35 (15 ± 8) years. Researchers reported
3–21 (7 ± 6) years of research experience.
The majority of specialists were orthopaedic physical ther-
apists (55%), followed by neurological (24%) and cardi-
orespiratory (10%). One participant reported to specialize
in paediatric physical therapy. Two participants did not
specify their area of specialization.
Reliability
Analysis of reliability of individual items indicates a trend
for higher reliability in items within the domain from
Rigor of Development (See Table 2). Intraclass correlation
coefficients (ICCs) for each domain of the AGREE instru-
ment for pairs of appraisers are presented in Table 3. No
systematic differences were observed that would indicate
that type of appraisers had any substantial impact on the
reliability obtained. Variation in reliability was observed
across domains with Rigor of Development demonstrat-
Table 1: Demographic description of physical therapy evaluators
Group Age Mean 
(SD)
Gender % Highest Degree %
Female Male Diploma Bachelors Masters Doctorate
Overall (n = 69) 40 (8) 96 4 9 58 32 1
Generalists ( n  =  2 1 ) 3 9  ( 9 ) 8 61 41 97 11 0 0
Specialists (n = 29) 39 (7) 100 0 7 79 14 0
Researchers (n = 19) 41 (9) 100 0 0 11* 84 5
* these two participants had significant research experience and were close to completion of Masters degreeBMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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ing the highest level of reliability. Few ICCs reached the
excellent benchmark of 0.75, if a single appraiser per-
formed the evaluation. ICC models that estimate the reli-
ability when appraisers were averaged using models (1,2)
for pairs or (1,6) across all six appraisers indicated sub-
stantial improvement in reliability if appraisals were aver-
aged across appraisers. When comparing the reliability
across different numbers of appraisers (Table 4) the
improvement in reliability was most notable when going
from two to three appraisers, with the exception of edito-
rial independence). Additional benefit for adding addi-
tional appraisers was inconsistent. Agreement on the
overall assessment of the CPG had low reliability for gen-
eralists and specialists and moderate reliability for
researchers. Quadratic weighting demonstrated some
improvement in reliability coefficients for generalists and
researchers, but not for specialists. (Table 5)
Validity
Face Validity/ User Feedback
Study participants provided feedback during training ses-
sions primarily with respect to the training session itself.
They found the opportunity to discuss the results with
others to be useful as a means of understanding the intent
of individual items. Only three participants had previ-
ously been exposed to the AGREE instrument and that
majority expressed positive comments about the value of
learning about the AGREE instrument. Some clinicians
expressed some anxiety about the role for CPGs and how
they might be used. None of the study participants pro-
vided any feedback when returning their mail packages.
The entry-level physical therapists (students) uniformly
agreed that the AGREE instrument provided a useful struc-
ture and guidance in the evaluation of the CPG. Students
compared the AGREE instrument to evaluation
instruments they had used for critical appraisal of differ-
ent study designs, such as clinical trials and systematic
reviews. Students frequently commented that these previ-
ous instruments had a more open-ended format and
expected the reviewer to understand issues in critical
appraisal with little direction as to expectations or scoring
criteria. Thus, they found the concrete nature of the
AGREE instrument and the clear instruction on interpreta-
tion to be a useful framework for the evaluation process.
Students stated that this direction increased their confi-
Table 2: Inter-rater reliability of AGREE instrument – individual items
Generalists Clinical Specialists Researchers Overall
Single Rater 
ICC
Average of 
Raters ICC
Single Rater 
ICC
Average of 
Raters ICC
Single Rater 
ICC
Average of 
Raters ICC
Single Rater 
ICC
Average of 
Raters ICC
Item 1 0.34 0.51 0.50 0.66 0.58 0.73 0.46 0.84
Item 2 0.28 0.44 0.03 0.05 -0.09 -0.19 0.25 0.67
Item 3 0.45 0.62 0.23 0.37 0.19 0.31 0.22 0.63
Item 4 0.58 0.74 0.65 0.79 0.75 0.86 0.67 0.92
Item 5 0.57 0.73 0.37 0.54 0.55 0.71 0.45 0.83
Item 6 0.43 0.60 0.62 0.76 0.69 0.82 0.55 0.88
Item 7 0.48 0.65 0.18 0.30 0.36 0.53 0.36 0.77
Item 8 0.88 0.93 0.77 0.87 0.78 0.88 0.83 0.97
Item 9 0.72 0.84 0.84 0.91 0.69 0.82 0.72 0.94
Item 10 0.61 0.76 0.54 0.70 0.66 0.80 0.62 0.91
Item 11 0.45 0.63 0.13 0.23 0.32 0.49 0.39 0.79
Item 12 0.61 0.75 0.46 0.63 0.55 0.71 0.63 0.91
Item 13 0.74 0.85 0.66 0.79 0.56 0.72 0.64 0.92
Item 14 0.57 0.73 0.61 0.76 0.70 0.82 0.65 0.92
Item 15 0.31 0.47 0.30 0.46 0.25 0.40 0.38 0.79
Item 16 0.39 0.56 0.49 0.66 0.46 0.63 0.43 0.82
Item 17 0.31 0.48 0.31 0.48 0.41 0.58 0.35 0.76
Item 18 0.32 0.48 0.60 0.75 0.42 0.59 0.52 0.87
Item 19 0.53 0.69 0.50 0.67 0.45 0.62 0.43 0.82
Item 20 0.48 0.65 0.40 0.57 0.49 0.66 0.43 0.82
Item 21 0.34 0.51 0.37 0.54 0.20 0.34 0.28 0.70
Item 22 0.53 0.69 0.15 0.27 0.42 0.60 0.26 0.68
Item 23 0.58 0.73 0.53 0.69 0.72 0.84 0.40 0.80
ICC – Intraclass correlation coefficient
Results statistically significant at the p < 0.05 level except where indicated by bold.BMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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dence that they had addressed all important issues.
Although students differed on their ratings for individual
questions, as well as the overall usefulness of the CPG
evaluated, the majority of students understood and cor-
rectly interpreted the intent of the items from all of the
AGREE domains. The majority of the students, 96 %,
stated that they would use the AGREE instrument in other
situations. A concern raised by the remaining 4% and
other students who would continue to use the instrument
was the length of the form and the amount of time
required to complete the evaluation, given the busy
nature of clinical practice.
Factor analysis
The factor analysis supported a 4-factor solution. The first
factor explained 45% of the variance and contained items
primarily from the Scope and Purpose or Rigor of Devel-
opment domains. The second component explained 12%
of the variance and contained items primarily from the
Clarity and Presentation or Applicability domains. The
Table 3: Inter-rater reliability of AGREE instrument domain scores
Scope & Purpose Stakeholder 
Involvement
Rigor of Development Clarity & Presentation Applicability Editorial 
Independence
Single 
Rater ICC 
(95% CI)
Average of 
Raters 
ICC- all 6 
raters or 3 
pairs of 2 
raters? 
(95% CI)
Single 
Rater ICC 
(95% CI)
Average of 
Raters ICC 
(95% CI)
Single 
Rater ICC 
(95% CI)
Average of 
Raters ICC 
(95% CI)
Single 
Rater ICC 
(95% CI)
Average of 
Raters ICC 
(95% CI)
Single 
Rater ICC 
(95% CI)
Average of 
Raters ICC 
(95% CI)
Single 
Rater ICC 
(95% CI)
Average of 
Raters ICC 
(95% CI)
Generalists 0.37
(0.11–0.59)
0.54 
(0.19–0.74)
0.71
(0.54–0.83)
0.83
(0.70–0.90)
0.81
(0.68–0.89)
0.89
(0.81–0.94)
0.41
(0.15–0.62)
0.58
(0.26–0.76)
0.65
(0.46–0.79)
0.79
(0.63–0.88)
0.60
(0.39–0.75)
0.75
(0.56–0.86)
Clinical 
Specialists
0.35
(0.10–0.56)
0.52
(0.18–0.72)
0.59
(0.39–0.74)
0.74
(0.56–0.85)
0.65
(0.47–0.78)
0.79
(0.64–0.88)
0.51
(0.29–0.69)
0.68
(0.45–0.81)
0.43
(0.19–0.63)
0.61
(0.32–0.77)
0.32 
0.06–0.54)
0.49
(0.11–0.70)
Researchers 0.17
(0.14–0.46)
0.30
(-0.32–0.63)
0.73
(0.54–0.85)
0.84 
(0.70–0.92)
0.77
(0.61–0.87)
0.87
(0.76–0.93)
0.47
(0.18–0.69)
0.64
(0.31–0.81)
0.47
(0.19–0.68)
0.64
(0.32–0.81)
0.59
(0.34–0.77)
0.75
(0.51–0.87)
Overall 0.40
(0.25–0.58)
0.80 
(0.66–0.89)
0.67
(0.54–0.80)
0.93
(0.87–0.96)
0.79
(0.68–0.88)
0.96
(0.93–0.98)
0.55
(0.40–0.72)
0.88
(0.80–0.94)
0.50
(0.35–0.68)
0.86
(0.76–0.93)
0.35
(0.19–0.54)
0.76
(0.59–0.88)
CI – confidence interval; ICC – intraclass correlation coefficient
Results statistically significant at the p < 0.5 level except where indicated by bold.
Table 4: Intraclass correlations for each AGREE instrument domain as a function of the number of raters
Scope & Purpose Stakeholder 
Involvement
Rigor of 
Development
Clarity & 
Presentation
Applicability Editorial 
Independence
Single 
Rater 
ICC
Average 
of 
Raters 
ICC
Single 
Rater 
ICC
Average 
of 
Raters 
ICC
Single 
Rater 
ICC
Average 
of 
Raters 
ICC
Single 
Rater 
ICC
Average 
of 
Raters 
ICC
Single 
Rater 
ICC
Average 
of 
Raters 
ICC
Single 
Rater 
ICC
Average 
of 
Raters 
ICC
2 Raters 0.37 0.54 0.71 0.83 0.81 0.89 0.41 0.58 0.65 0.79 0.60 0.75
3 Raters 0.38 0.64 0.71 0.88 0.82 0.93 0.54 0.78 0.66 0.85 0.38 0.65
4 Raters 0.41 0.73 0.64 0.88 0.77 0.93 0.51 0.80 0.54 0.82 0.35 0.69
5 Raters 0.42 0.78 0.69 0.92 0.79 0.95 0.51 0.84 0.57 0.87 0.38 0.76
6 Raters 0.40 0.80 0.67 0.93 0.79 0.96 0.55 0.88 0.51 0.86 0.35 0.76
ICC = Intraclass correlation coefficient
Table 5: Agreement on whether a CPG would be recommended 
or not
Pair of Raters Kappa (unweighted) Kappa (quadratic weights)
Generalists 0.20 0.34
Specialists 0.25 0.22
Researchers 0.39 0.47
A Kappa was calculated on the final overall rating question whether or 
not a CPG should be using with the data dichotomized as YES 
(strongly recommend or recommend with provisos) or NO (Would 
not recommend or unsure) or by using quadratic weighting to 
compare the strength of recommendation (Strongly, with provisos, 
would not, unsure).BMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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third factor explained 7.7% of the variance and contained
all of the items from the Stakeholder Involvement
domain, all of the Editorial Independence items and ques-
tion 13 from Rigor of Development, which pertains to
whether the guideline has been externally reviewed by
experts. The fourth component explained 5.6 percent of
the variance and contained item 11 regarding health ben-
efits/side effects and item 15 regarding whether recom-
mendations were specific and unambiguous. Item means
and their loadings are presented in Table 6.
Construct validity
The construct that the CPGs developed by expert guide-
line development groups would have a higher score on
the domain Rigor of Development was supported (See
Table 7). The construct that therapists would be more
likely to recommend for usage a CPG with a higher quality
on the domain Rigor of Development was also supported
(mean of 76 vs. 58 p <0.001).
Criterion validity
The correlation between overall assessment and the
domain scores ranged from low (0.38) to moderate
(0.64), with the highest correlation being observed for the
Rigor Of Development domain. (Table 8)
Discussion
The study findings suggest that the AGREE instrument is
reliable and valid when used by physical therapists to
evaluate CPGs. While some differences exist between the
results reported in the original validation study authored
by the AGREE Collaboration, the similarities far outweigh
the differences. This would suggest that the process of
evaluating CPGs using the AGREE instrument can be
transferred to physical therapy practice to support the
Table 6: Results of factor analysis (principal components with varimax rotation)
Item Mean Std. Deviation Components
1234
Scope and Purpose
Q1 3.4003 .72614 .690 .339 .271 .217
Q2 2.9681 .68948 .803 .213 .129 .296
Q3 3.3961 .51941 .393 .489 .016 .430
Stakeholder Involvement
Q4 2.6814 1.07262 .336 .422 .661 .093
Q5 1.7517 .89553 .179 .173 .739 .058
Q6 2.8331 .89717 .195 .294 .726 .259
Q7 1.6664 .75710 .255 .290 .675 .175
Rigour of development
Q8 2.7344 1.21287 .902 .096 .247 -.087
Q9 2.6533 1.20139 .913 .112 .229 -.123
Q10 2.6314 1.05247 .800 .132 .384 .066
Q11 2.9492 .76769 .059 .339 .302 .682
Q12 2.9811 1.00409 .626 -.058 .223 .514
Q13 2.3556 1.16306 .422 .273 .617 .213
Q14 1.9425 .99370 .323 .668 .090 .044
Clarity and presentation
Q15 3.2250 .73262 .132 .200 .149 .864
Q16 3.2269 .77070 .022 .607 .241 .322
Q17 3.1631 .71880 .093 .606 .453 .400
Q18 2.3342 .98180 .091 .671 .449 .273
Applicability
Q19 2.2072 .94797 .158 .830 .231 .005
Q20 1.9500 .83211 .172 .818 .176 -.073
Q21 2.2336 .80322 -.017 .775 .299 .237
Editorial Independence
Q22 2.1453 .90158 .451 .108 .669 .045
Q23 1.7575 .92802 .178 .305 .452 -.436
This table presents the results of the final 4 factor solution to factor analysis. Bolded cells shown the factor for which each item loaded most 
strongly. Results are grouped according to the Domains of the AGREE.BMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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translation of higher quality CPGs into physical therapy
health services.
Typically, individual item reliability is of little relevance
when evaluating the properties of a measurement scale, as
items are not intended to be used in isolation. However,
it may be useful from a practical point of view to form
hypotheses about were further training might be neces-
sary, if it appears that appraisers have particular difficulty
with certain items. As discussed above, one must be care-
ful in interpreting reliability coefficients in isolation, par-
ticularly for instruments like the AGREE where some
items have "relatively true" scores and others have a spec-
trum of true scores. For the AGREE this spectrum might
exist on application items. Thus, we would expect low
item reliability might result from items where there is
large measurement error, but also from items where there
is substantial variability in how the item might apply in
different circumstances. Our data support this. Low relia-
bility was evident on items such as whether the guideline
was editorially independent (2/8 ICCs were not greater
than 0) and whether key review criteria for monitoring or
audit had been provided (2/8 ICCs were not greater than
0). Study participants also appeared to have difficulty
interpreting these items during the training session and
thus these disagreements may reflect a lack of consensus
about the meaning of these items. In some CPGs informa-
tion on Editorial Independence is contained in footnotes
and was missed by some evaluators. Improvements in
reliability on these items might be anticipated with fur-
ther training. Other items where low reliability was
observed included whether the clinical question was spe-
cifically described (6/8 ICCs were not greater than 0) and
whether the patients to whom the guideline applied were
specifically described (2/8 ICCs were not greater than 0).
During training, participants appeared to understand
these questions, although expectations about what consti-
tuted an appropriate description of the clinical question
or patient population tended to vary according to the par-
ticipant's level of expertise in that given clinical area. Thus,
disagreements on these items may partially relate to dif-
ferences in priorities or familiarity with relevant issues
between participants. Further training is unlikely to
enhance reliability in this case, but raises the question
about the importance and specificity of relevant clinical
expertise when selecting evaluators. Although our intent
was to evaluate the importance of clinical expertise, we
classified participants quite broadly. Participants classi-
fied as clinical specialists were provided CPGs within their
broad area of practice; but, we did not ascertain whether
in fact the specific topic of the CPG was an area in which
they actually did have knowledge or experience. For exam-
ple, a clinician with expertise in musculoskeletal practice
might practice primarily in a narrower area within the
field, such as, rheumatology, upper extremity, lower
extremity, joint replacements etc. In such cases, their
familiarity with the salient features of the specific condi-
tions might be less detailed and result in a differential
evaluation regarding whether the clinical population had
Table 7: Hypothesis test: rigour of development is greater where panel is known to have methodology expertise
Rater Expert Panel No or Uncertain Expertise p
Generalist #1 79 58 0.002
Generalist #2 79 57 0.001
Specialist #1 73 58 0.015
Specialist #2 75 65 0.09
Researcher #1 72 57 0.02
Research #2 80 61 0.014
All 6 appraisers combined 78 59 <0.001
This table contains the scores for the Agree Domain on Rigour of Development. CPGs were classified as having an expert panel if 1) there were 
more than 3 authors listed (or an agency) and 2) there was an experienced CPG methodologist clearly identified as a panel member or if one of the 
study investigators was recognized as such. All others were classified as "No or Uncertain Expertise". The p value for the independent samples t-
test is shown.
Table 8: Correlation of domain scores with overall assessment of 
AGREE
Domain Correlation with Overall Rating
Stakeholder Involvement 0.59
Scope and Purpose 0.52
Rigour of Development 0.64
Clarity and Presentation 0.62
Applicability 0.49
Editorial Independence 0.38
Kendall's Tau-b correlations were conducted between the mean 
rating of the over assessment of the CPG across all raters as 
compared to the mean of each Domain score. As hypothesized the 
correlation was highest with Rigour of development.BMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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been appropriately defined. Future investigations should
focus on content knowledge in a more specific sense to
determine the importance of this issue when selecting
evaluators.
It is not uncommon for the policy developers to use relia-
bility data to set standards for the number of appraisers
required when establishing guideline evaluation proc-
esses. Our data provide little direction in this regard,
except to suggest that more than two appraisers are advis-
able. This is consistent with the minimum recommenda-
tion of 2 made by the AGREE Collaboration. [7]
Measurement theory suggest that additional appraisers/
ratings should produces higher levels of reliability[20] as
do the AGREE Collaboration when stating that 4 apprais-
ers is preferable. Our data did not follow this trend,
beyond three appraisers. Our study evaluated the reliabil-
ity of appraisers performing their assessment in isolation.
This process replicates that which might be used by a
working committee independently assessing quality
scores. However, individual therapists might also need to
evaluate CPG when no committee has been established to
do so. In these cases, we would recommend three or more
appraisers should still be recruited. We recognize that
when evaluating CPGs, it is not just the score, but the
process that is important. Adding additional appraisers
with different perspectives may increase the variability/
disagreements. In fact, our data support this, as quadratic
weighting of disagreements improved reliability coeffi-
cients in generalists and researchers, but not specialists.
Specialists tended to disagree on whether a CPG should be
used are not, but were less uncertain about that
recommendation. We suggest the ideal approach to eval-
uation of CPGs is one where a group of potential end-
users with clinical and guideline expertise work together
to review a potential CPG by using the AGREE to facilitate
a consensus process to determine both the quality and rel-
evance to practice. These quality ratings should be dissem-
inated to the relevant clinical communities. We recognize
that the ideal process will not always be possible. Individ-
ual clinicians who must make decisions about utilization
of CPGs should recruit colleagues to assist with the evalu-
ation process before modifying their clinical practice
based on CPGs with unknown validity.
Although interpretation of validity analyses is complex
and requires some subjective decisions, overall our valid-
ity analyses are supportive of the AGREE instrument and
are substantively similar to that reported by the AGREE
Collaboration for 33 medically based CPGs[14] A factor
analysis structure which suggests that the concepts
measured by the AGREE are similar to the Domains
described by the AGREE underlies the content and struc-
tural validity of the scale. The factor analysis was strongly
supportive of the domains of Stakeholder Involvement
and Editorial Independence. This would support unique-
ness of items within these domains. The largest factor con-
tained items from the domain Rigor of Development as
well as the first two items in Scope and Purpose. Concep-
tually these two items, which require specific objectives
and a well-defined clinical question, fit well with a process
of rigorous development. That the largest factor relates to
methodological issues supports the AGREE as an evalua-
tive tool. The second factor contained the items regarding
whether the patients were specifically described, whether
procedures for updating the guideline were provided, all
of the items from the applicability domain and 3/4 items
from the clarity and presentation. Clarity of presentation,
applicability and a defined patient population may all
relate to the ability to implement CPGs and thus all retain
a conceptual relationship to the domains Applicability or
Clarity of Presentation described by the AGREE Collabo-
ration. The third factor contained all items of the stake-
holder involvement as well as the additional question in
rigor of development addressing whether experts had
externally reviewed the guideline. In general, these results
support stakeholder involvement as a subscale and
include external involvement within this distinct domain.
The fourth factor contained only two items, one the item
on health benefits/ side effects and a second whether rec-
ommendations were specific and unambiguous. This fac-
tor explained a small percentage of the variance and
contained only two items, making it difficult to relate
these results to the factor analysis presented by the AGREE
Collaboration. While the results vary somewhat from
those reported by the AGREE Collaboration, there is sub-
stantial similarity, particularly when one examines the
concepts that are represented by the items that clumped
together. We view our factor analysis results with caution
given the small sample sizes. The AGREE Collaboration
study use 100 guidelines and conducted this analysis dur-
ing the field-testing prior to inclusion of item 23. Our
analysis included only 56 guidelines. We did not conduct
formal sample size calculations, as practical limitations
on guideline availability determined our sample size.
Rules of thumb suggest ten "subjects" per item for factor
analysis, requiring 230 CPGs for a well-powered analysis.
Thus, some inherent instability should be expected in the
factor analyses conducted to date. With the proliferation
of CPG, we expect that larger samples might be evaluated
in future studies and provide more definitive results on
the factor validity of the AGREE instrument.
Construct validity tests also supported the validity of the
AGREE instrument. Constructs were developed to repli-
cate those used in the previous validation of the
AGREE[14] and provided similar findings. Despite our
inability to be confident about whether some CPGs had a
methodologist, we still found large differences between
the Rigour of Development Domain score obtained whereBMC Health Services Research 2005, 5:18 http://www.biomedcentral.com/1472-6963/5/18
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we could identify a team containing a methodologist as
compared to where this was not present or unclear (21
point difference). The AGREE Collaboration found a 9
point advantage in this domain for guidelines developed
within a guideline development program and 19 points
for those developed as national initiatives. Similarly, our
correlations between overall assessment scores and those
reported for Rigor of Development (0.64) concurred with
those reported by AGREE Collaboration data (0.87) in
that both suggest a substantive relationship.
Overall, our findings were remarkably consistent with
those reported by the AGREE collaboration when validat-
ing the AGREE as used by medical practitioners[14] Vali-
dation by independent groups in different settings
provides a stronger foundation for any instrument. These
findings can be used to increase confidence in the current
practice of different health care disciplines to use the
AGREE to facilitate the evaluation of CPGs.
Conclusion
1. The AGREE instrument is reliable and valid when used
by physical therapists to assess the quality of clinical prac-
tice guidelines
2. A minimum of three appraisers should be used to opti-
mise reliability, although issues on effecting knowledge
transfer or maximizing validity might increase these
requirements.
3. There is no evidence that specific types of physical ther-
apists provide more reliable scores. As this study did not
address whether familiarity with the actual content of the
CPG influenced reliability, this should be studied in the
future.
4. There is evidence that guidelines developed with the
assistance of experienced guideline developers are more
rigorous.
5. The AGREE instrument was found to be useful in assist-
ing both novice and experienced therapists in evaluation
of clinical practice guidelines. The majority of therapists
would continue to use the instrument.
6. Validity analysis supported the majority of results
reported by the AGREE Collaboration)[14] The type of
CPGs and evaluators were different in the current study
supporting the validity of this instrument across a spec-
trum of circumstances.
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